Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis

Inclusion Criteria: * Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in native coronary vessels * Written, informed consent by the patient or her/his legally-authorized representative for participation in the study * In women with childbearing potential a negative pregnancy test is mandatory. Exclusion Criteria: * Target lesion located in the left main trunk. * Target lesion located in the bypass graft. * In-stent restenosis. * Cardiogenic shock. * Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance. * Known allergy to the study medications: Clopidogrel, Rapamycin, Probucol, Zotarolimus, stainless steel or cobalt chrome. * Inability to take clopidogrel for at least 6 months. * Pregnancy (present, suspected or planned) or positive pregnancy test. * Previous enrollment in this trial. * Patient's inability to fully cooperate with the study protocol.